- ISIN
- US98420X1037
- CUSIP
- 98420X103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 16, 2017
Highlights
- Market Cap
- $501.37M
- Enterprise Value
- $285.92M
- EPS (TTM)
- -$1.39
- Total Revenue (TTM)
- $9.01M
- Gross Profit (TTM)
- $6.88M
- EBITDA (TTM)
- -$108.91M
- Year Range
- $1.35 - $4.83
- Target Price
- $11.00
- ROA (TTM)
- -36.90%
- ROE (TTM)
- -59.20%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XFOR Performance Chart
X4 Pharmaceuticals, Inc. (XFOR) is down 0.8% since the beginning of the year. At $4 per share, XFOR is trading 17.8% below its 52-week high of $5. Investors who bought $1,000 worth of XFOR shares 5 years ago would now be looking at an investment worth $15.
Loading charts...
Returns By Period
X4 Pharmaceuticals, Inc. (XFOR) has returned -0.75% so far this year and 0.25% over the past 12 months.
X4 Pharmaceuticals, Inc.
- 1D
- -1.73%
- 1M
- -5.70%
- YTD
- -0.75%
- 6M
- 22.15%
- 1Y
- 0.25%
- 3Y*
- -60.82%
- 5Y*
- -56.94%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
XFOR Monthly Returns History
Based on dividend-adjusted daily data since Nov 16, 2017, XFOR's average daily return is +0.01%, while the average monthly return is -1.29%.
Historically, 34% of months were positive and 66% were negative. The best month was Nov 2018 with a return of +190.3%, while the worst month was Jun 2018 at -78.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, XFOR closed higher 44% of trading days. The best single day was Nov 27, 2018 with a return of +255.2%, while the worst single day was Jun 28, 2018 at -78.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.50% | -7.03% | 20.06% | -1.45% | 5.90% | -7.89% | -0.75% | ||||||
| 2025 | -4.57% | -43.57% | -40.17% | -39.23% | -21.11% | -44.12% | -11.58% | 123.51% | -8.92% | 18.13% | -9.90% | 9.89% | -81.82% |
| 2024 | -6.81% | 24.21% | 43.21% | -19.42% | -9.82% | -42.57% | 37.95% | -12.51% | -4.39% | -25.27% | -21.43% | 86.67% | -12.51% |
| 2023 | 3.73% | -8.93% | -7.25% | 68.97% | 38.10% | -4.43% | -7.73% | -28.49% | -14.84% | -26.56% | -2.56% | 7.50% | -15.56% |
| 2022 | -10.04% | -27.18% | 16.67% | -26.29% | -6.20% | -20.25% | 32.64% | -22.65% | 72.71% | 11.11% | -21.05% | -33.80% | -56.64% |
| 2021 | 21.46% | 22.54% | -10.03% | -2.67% | 13.37% | -31.58% | -11.54% | -10.78% | 3.12% | -8.51% | -8.06% | -48.54% | -64.39% |
Benchmark Metrics
X4 Pharmaceuticals, Inc. has an annualized alpha of -12.32%, beta of 1.06, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 17, 2017.
- This stock participated in 185.51% of S&P 500 Index downside but only -62.94% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -12.32%
- Beta
- 1.06
- R²
- 0.02
- Upside Capture
- -62.94%
- Downside Capture
- 185.51%
Return for Risk
Risk / Return Rank
XFOR ranks 47 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for X4 Pharmaceuticals, Inc. (XFOR) and compare them to S&P 500 Index.
| XFOR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.24 | ||
| Sortino ratioReturn per unit of downside risk | -1.94 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.41 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | 0.00 | 2.93 | -2.92 |
| Martin ratioReturn relative to average drawdown | 0.01 | 13.52 | -13.51 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the X4 Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the X4 Pharmaceuticals, Inc. was 99.97%, occurring on Aug 11, 2025. The portfolio has not yet recovered.
The current X4 Pharmaceuticals, Inc. drawdown is 99.92%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -99.97%Aug 2025 | 7y 4mo | — | 8y 2moMar 2018 - now |
2017 bear market2017 | -41.18%Dec 2017 | 14d | 3mo | 3mo 14dNov 2017 - Mar 2018 |
2018 pullback2018 | -6.41%Mar 2018 | 3d | 1d | 4dMar 2018 - Mar 2018 |
2017 pullback2017 | -0.71%Nov 2017 | 0s | 3d | 3dNov 2017 - Nov 2017 |
Drawdown Indicators
| XFOR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.97% | -56.78% | -43.19% |
Max Drawdown (1Y)Largest decline over 1 year | -66.98% | -9.10% | -57.88% |
Max Drawdown (3Y)Largest decline over 3 years | -98.10% | -18.90% | -79.20% |
Max Drawdown (5Y)Largest decline over 5 years | -99.50% | -25.43% | -74.07% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.92% | -0.74% | -99.18% |
Average DrawdownAverage peak-to-trough decline | -91.52% | -10.72% | -80.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.77% | 1.97% | +27.80% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of X4 Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how X4 Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for XFOR relative to other companies in the Biotechnology industry. Currently, XFOR has a P/S ratio of 31.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XFOR in comparison with other companies in the Biotechnology industry. Currently, XFOR has a P/B value of 3.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with XFOR
Add X4 Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XFOR